Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues

Ultragenyx Pharmaceutical and partner GeneTx Biotherapeutics have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial that was previously paused after some patients temporarily lost the ability to walk.